overview | biapenem side chain is a pharmaceutical raw material and can be used to produce biapenem antibiotic drugs. Biapenem (Biapenem,LJC 10627) is a carbopillinene antibiotic for injection developed by Japan Lederle Company and American Cyanamide Company in 1989. Currently, Phase III clinical study has been completed in Japan and is awaiting approval for listing. The most notable feature of this product is 1 β-methyl carbapenem with bicyclic triazole at the 2-position S. Structure-activity relationship studies show that the presence of its side chain quaternary ammonium cation center is the key to affect the permeability of the outer membrane, making biapenem 2-4 times the activity of imipenem (Imipenem) in inhibiting Pseudomonas aeruginosa and anaerobic bacteria, and 4-8 times the activity of inhibiting drug-resistant Pseudomonas aeruginosa (Meropenem), which is more effective than ceftazidine in Acinetobacter and anaerobic bacteria. |
current situation of penm drugs in China | penm drugs are antibiotics with the widest antibacterial spectrum and strong antibacterial activity so far, so they play an important role in the last line of defense against clinical severe infection. In recent years, due to the severe problem of drug-resistant bacteria, the global and domestic use of this type of drug has increased rapidly. Imipenem-cilastatin, panipenem-betametron, Meropenem, Biapenem (biapenem side chain), ertapenem and doniepenem have been listed worldwide. However, the penem class is clinically used as a second-line drug. The government's guiding principles for the rational use of antibiotics and the high price also greatly limit the expansion of the number of penem used. These factors determine that this type of drug is still a kind of high value-added, small-scale "noble" variety in the short term. In 2008, the sales scale of Peinan terminals in the Chinese market was 1.89 billion yuan (equivalent to 0.278 billion US dollars), accounting for 9% of the total sales of nearly 3 billion US dollars in the world. Sales volume reached about 12.43 million. Consumption of raw materials 5~6 tons/year, of which domestic raw materials are 1.9 tons (including 1.8 tons of meropenem and 0.14 tons of imipenem), accounting for 36%. In the raw material export market, in 2008, China's three major products-meropenem, imipenem and intermediate 4-AA, their raw material exports were 6 tons, 1.3 tons and 40 tons respectively, accounting for more than 60% of the demand for raw materials in the global generic drug market. Since 2009, the international market demand has continued to grow, and the technical cost of Peinan raw materials and intermediates in my country has gradually gained advantages. In particular, Meropenem has a large share in the international market and has a certain price voice. 2009's annual exports of Meropenem and 4-AA are expected to reach 8 tons and 50 tons respectively, with a growth rate of about 30%. Peinan drugs will continue to grow rapidly and steadily at their own "pace. |